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BelgiumA B S T R A C TBackground: In systems with public health insurance, coverage
decisions should reﬂect social values. Deliberation among stakehold-
ers could achieve this goal, but rarely involves patients and citizens
directly. Objectives: This study aimed at evaluating the acceptability,
and the perceived beneﬁts and risks, of public and patient involve-
ment (PPI) in coverage decision making to Belgian stakeholders.
Methods: A two-round Delphi survey was conducted among all
stakeholder groups. The survey was constructed on the basis of
interviews with 10 key stakeholders and a review of the literature
on participation models. Consensus was deﬁned as 65% or more of the
respondents agreeing with a statement and less than 15% disagreeing.
Eighty stakeholders participated in both rounds. They were deﬁned as
the Delphi panel. Results: Belgian stakeholders are open toward PPI
in coverage decision processes. Beneﬁts are expected to exceed risks.
The preferred model for involvement is to consult citizens or patients,
within the existing decision-making structures and at speciﬁc milestones
in the process. Consulting citizens and patients is a higher level of
involvement than merely informing them and a lower level thanee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.12.015
emput@kce.fgov.be.
ondence to: Irina Cleemput, Belgian Health Care K
00 Brussels, Belgium.letting them participate actively. Consultation involves asking non-
binding advice on (parts of) the decision problem. According to the
Delphi panel, the beneﬁts of PPI could be increasing awareness among
members of the general public and patients about the challenges and
costs of health care, and enriched decision processes with expertise
by experience from patients. Potential risks include subjectivity,
insufﬁcient resources to participate and weigh on the process,
difﬁculties in ﬁnding effective ways to express a collective opinion,
the risk of manipulation, and lobbying or power games of other
stakeholders. Conclusions: PPI in coverage decision-making proc-
esses is acceptable to Belgian stakeholders, be it in different
ways for different types of decisions. Beneﬁts are expected to
outweigh risks.
Keywords: Belgium, coverage decisions, patient participation, policy,
public involvement.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Involvement of the general public and patients in the resource
allocation decision-making process is a way to incorporate
societal values in decisions. Involvement is “the spectrum of
processes and activities that bring the public into the decision-
making process” and is associated with activities beyond routine
democratic processes [1]. Public and patient involvement (PPI) in
health care decision making helps in legitimating decisions [2–4]
and in dealing with societal and economic evolutions, such as
increasing demand for health care and higher patient expect-
ations in a context of budgetary constraints [5]. Moreover, it could
engender the trust and conﬁdence in the health system [6] and
engage communities and individuals in health action [3,7].Public involvement in coverage decisions implies a shift from
professional dominance of technocratic experts in decision-
making processes toward more empowerment of lay people [8].
In deliberation-driven models, as in Belgium and Austria,
health care coverage decisions are prepared by a multistake-
holder appraisal committee, consisting of scientists, sickness
funds, pharmaceutical industry, medical professionals, health
care institution representatives, and politicians. Patients or citi-
zens are usually not directly represented in the committees.
Nevertheless, the committees are deemed to take balanced
decisions in the best interest of the citizens and patients, taking
resource constraints into account.
It is unclear to what extent the committees would value PPI in
decision-making processes, in which cases, and in which wayociety for Pharmacoeconomics and Outcomes Research (ISPOR).
nowledge Centre (KCE), AC Kruidtuin, Doorbuilding (10th Floor),
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at different levels: the strategic level, relating to global priorities
for health care resource allocation, and the operational level,
relating to the reimbursement of individual products or services.
This study assesses the acceptability to stakeholders of PPI in
health care resource allocation decision-making processes, pos-
sible reasons for PPI, and perceived beneﬁts and risks of such
involvement.Methods
General Design: Delphi Approach
The aim of assessing the opinions of stakeholders in health care
coverage regarding PPI calls for a qualitative research approach.
We used a two-round Delphi approach, combining elements from
the modiﬁed Delphi approach and elements from the policy
Delphi approach [12], to survey a group of Belgian stakeholders
currently involved or not (yet) involved in decision-making
processes. Patient organizations are, for example, not involved
(yet) in Belgium [13].
The Delphi approach uses a series of sequential question-
naires or “rounds,” interspersed by controlled feedback, that seek
to gain the most reliable consensus of opinion of an “expert
panel” [13]. As in the modiﬁed Delphi approach, we ﬁrst per-
formed face-to-face interviews to construct the survey for the
ﬁrst Delphi round. As in a policy Delphi approach, we invited
policymakers and other stakeholders to participate in a two-
round survey. The research protocol followed the guidelines for
qualitative research of the Belgian Health Care Knowledge Centre
[14]. Only those respondents who participated in both Delphi
rounds were considered part of the Delphi panel. Consensus was
deﬁned as at least 65% of the participants agreeing with a
statement and a maximum of 15% disagreeing. The Delphi survey
was performed by e-mail to avoid direct confrontation and the
risk of excessive inﬂuence of powerful stakeholder groups.
Figure 1 presents the consecutive steps of our Delphi process.
Preliminary Phase: Interviews with Key Stakeholders and
Literature Review
The preliminary phase of our Delphi process consisted of semi-
structured interviews with 10 stakeholders and a narrative
review of the literature on PPI in resource allocation decision
making. The aim of the stakeholder interviews was to identify
contextual factors and experiences with PPI that were important
to know for the construction of the ﬁrst Delphi survey and for the
interpretation of its results. An interview guide consisting of
three parts was used. Part 1 consisted of nine questions relating
to experience with PPI and the presumed purpose of PPI. Part 2
included six questions relating to ways to involve the public and
patients. In part 3, the interviewees were asked to give examplesPreliminary phase
• Face-to-face interviews
• N=10
• April 2012
• Literature review
• February 2012-May 
2012
• Stakeholder 
informaon session 
• N=63
• 14 May 2012
Round 1 Delphi 
process
• N=107
• Sent: 21 May 2012 | 
Closed: 1 June 2012
Fig. 1 – Three-roundof PPI from Belgium or elsewhere, followed by semi-structured
discussion about these examples.
All interviewees had a key role in the current health care
system. They consisted of politicians, civil servants, representa-
tives of the medical profession and care institutions, patient
organizations, and sickness funds. They were selected because of
their expected general overview of concerns and sensitivities of
stakeholders with respect to PPI in decision making. The inter-
viewees were not excluded from the Delphi panel. After the
interview, they were treated in the same way as other invited
stakeholders.
The literature review was performed to be able to describe
different implementation models for PPI in health care resource
allocation policy. We started from existing reviews on PPI
[1,5,7,15] and applied the snowballing principle to the reference
lists of these reviews to select additional articles for full-text
review. Articles were included if they added new information or
fresh insights. These included studies on PPI and consultation
methods, practice and evaluation, and theoretical and conceptual
frameworks of the design and evaluation of PPI processes. The
review identiﬁed the dimensions of involvement and the pros
and cons of different implementation models. The dimensions
used for describing PPI models were level or type of the decision
[16–18], role of the citizen or patient representative [16,19,20],
intensity of involvement [5,16,18,21–23], and involvement
modalities.
The level of the decision can be the strategic or the operational
level. The strategic level refers to general priority setting for
resource allocation. It relates to questions such as “should we,
as a society, give priority to the expansion of home care services
for chronically ill elderly patients or to more effective curative
treatments for cancer patients when allocating our limited public
resources for health care.” The operational level relates to the
coverage of speciﬁc products or services for the entire population,
a subgroup of patients, or individual patients. They refer, for
instance, to decisions regarding the coverage of a new insulin
analog for the treatment of diabetes.
The role of the public or patient representative can be that of a tax
and social contributions payer (citizen), or that of an expert by
experience (patient). This simpliﬁed presentation of possible
roles was chosen to avoid confusion among the participants in
the Delphi panel. It should be acknowledged, however, that the
distinction between public and patient is in a way artiﬁcial
because the public includes past and current as well as future
patients. In addition, individuals easily move between roles
[16,19]. We did not, as some authors do, deﬁne patient involve-
ment as referring to “decisions about one’s own care” only [20].
The intensity of involvement refers to “the extent to which
individuals have control over the decision-making process” [16].
A broad range of levels of involvement has been documented in
the literature [5,16,18,21–23]. We used the spectrum of the
International Association for Public Participation (IAP2), but
adapted the labels to avoid confusion with the general termRound 2 Delphi 
process
• N=80
• Sent: 12 June 2012 | 
Closed: 25 June 2012
Feedback session 
on Delphi survey 
results 
(stakeholders)
• N=39
• 16 October 2012
Delphi process.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 7 7 – 4 8 3 479“involvement,” which encompasses all levels of intensity in our
framework. The most basic level of involvement is to inform the
public or patients, which mean they are attributed no power. The
highest degree of power transfer happens when decisions are
actually taken by the public, labeled as “public decides” in our
framework instead of “empower” in the IAP2 spectrum. Consul-
tation, debate (instead of involvement), and codecision (instead
of “collaboration”) are intermediate levels of involvement, in
increasing order of power transfer.
Dimensions relating to the modalities of PPI encompass where the
involvement takes place (inside current decision-making organs
[e.g., expert committees] or outside existing organs [e.g., in a
speciﬁcally established consultative commission]); when the public
and patients are involved (at all deliberations, only at milestones
during the decision-making process, only at the end of the process,
or only just before or after a decision is taken); how many citizens
and patients are involved (only one or more representatives),
duration of representation (ﬁxed or a changing representation),
and how the involvement is organized (by written and/or oral
contributions, face-to-face, or from a distance). Also, the impact of
the involvement on the decision is considered, that is, should the
advice be binding or nonbinding, and if nonbinding, should devia-
tions from the public’s and patients’ advice be justiﬁed.
Before launching the ﬁrst round of the Delphi process, a face-
to-face meeting was organized to inform all stakeholders who
would be invited to participate in the Delphi survey about the
Delphi process, and to show some results of the literature review.
Participants could ask questions and give suggestions for the
study. Sixty-three persons participated in the session.
First Delphi Round
The questionnaire for the ﬁrst Delphi round was structured in
four parts: Part 1: General opinion about PPI, including rationale for
involvement. Part 2: Perceived beneﬁts and risks of PPI.
 Part 3: Preferences with regard to the intensity of PPI.
 Part 4: Preferences with regard to the modalities of PPI.In parts 3 and 4, a distinction between strategic and opera-
tional decisions was made.
Participants were asked to what extent they agreed with a
number of statements, how important they considered speciﬁc
items, or which response option they preferred out of a list of
options. For the analysis, each pair of the following response
categories was merged to determine whether consensus was
reached: “very important” and “important,” “fully agree” and
“agree,” “not important” and “not important at all,” and “not
agree” and “not agree at all.” For questions in which respondents
had to choose their preferred response option, the proportion of
respondents choosing each option was calculated. When this
proportion was higher than 65%, consensus on that item was
assumed.
Invited stakeholders also received a background document,
explaining the concepts used and the framework of PPI. This
document was kept brief to ensure that participants would read
the document before answering the questions. The complete
version of the questionnaires and background document are
available online in Dutch and French [24,25].
Second Delphi Round
The second Delphi round started after the analysis of responses
from the ﬁrst round. Stakeholders who participated in the ﬁrst
round received a synthesis of the ﬁrst round results and a second
questionnaire. The second questionnaire built further on theelements for which consensus was reached in the ﬁrst round: it
explored the acceptability of practical proposals for involving the
public and patients when there already was consensus on the
principle or the level of involvement. Proposals related, for instance,
to the role and number of representative(s) to be involved (one or
more patient and/or citizen), where and when the involvement
should take place, and what should be the impact for decision
makers, given the acceptance of a minimal level of PPI for
strategic and operational decisions. In combination with the
other dimensions of involvement, all these practical dimensions
make up the involvement models (Fig. 2). In addition, the second
round further explored elements for which no consensus was
reached in the ﬁrst round.
The questioning was simpliﬁed in the second round and
consisted of yes/no answers for most items. New items sugges-
ted by respondents in the ﬁrst round were added if at least
two participants had suggested them. Consensus was deter-
mined by calculating the proportion of respondents answering
“Yes.”
Sampling
Nearly 600 persons representing several stakeholders in Bel-
gium were invited to participate in the ﬁrst Delphi round. They
included representatives of consumer and patient associa-
tions, politicians/decision makers at the national level (parlia-
ment), high-level civil servants and policymakers at the
regional level, and members of the advisory councils and
committees at the National Institute for Health and Disability
Insurance (NIHDI).
The NIHDI advisory councils and committees prepare deci-
sions for the decision makers (i.e., the ministers). They are
composed of several stakeholders in health care decision making:
civil servants, representatives of sickness funds, academics,
medical professions, care organizations, pharmaceutical compa-
nies, manufacturers of medical devices, employer organizations,
and trade unions. Consumers’ and patients’ associations are
currently not involved in the decision-making processes and
were therefore added to our sample. They were invited on the
basis of a nominative list of persons who showed interest in the
subject, for instance, by participating in earlier events relating to
PPI in health care (for patient organizations) or by direct contact
(for consumer organizations).
Some individuals belong to several stakeholder groups. For
example, an academic can be a medical doctor working in a
health care institution; thus, he or she belongs to three different
stakeholder groups. People can also be members of several
decision-making organs. For example, a representative of the
sickness funds can be a member of the insurance council as well
as of the drug reimbursement committee at the NIHDI. This
makes it difﬁcult to give an overview of the number of people
involved in the study per stakeholder group. For this qualitative
study, however, this is less of an issue, because the aim was to
cover the variety in positions relating to PPI among stakeholders,
and not to obtain statistical representativeness of stakeholders’
characteristics [14].Results
Description of the Delphi Panel
One-hundred seven stakeholders participated in the ﬁrst Delphi
round. Eighty stakeholders participated in both the ﬁrst and
second Delphi rounds (Table 1). All types of stakeholders were
represented in the Delphi panel. The majority was active as full
member or substitute in an advisory organ of the NIHDI.
OperationalStrategic
Citizen Patient
Only one representativeMore than one representative
Informing Consulting Participation in debate Co-decision Sole decision maker
Non-binding advice Advice to be taken into 
account at the moment of 
taking the decision
Decision to be justified when 
different from citizens’ and 
patients’ advice
Inside existing organs Outside existing organs
After the decisionBefore the decisionAt the end of the 
decision-making process
At each milestone of the 
process
Type of decision?
Who?
How many?
Intensity?
Impact?
When?
Where?
Fig. 2 – Preferred general model for public and patient involvement. The shaded boxed are the options within each
dimension for which consensus was reached among the participants in the Delphi survey.
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More than 70% of the respondents considered PPI in health care
decision making (very) important. Eight percent of the respond-
ents who did not consider PPI important came from diverse
categories of stakeholders.
Reasons why PPI was considered important were multiple and
ﬁtted with several theoretical rationales for PPI described in the
literature. The consequentialist, technocratic, or consumer
rationale considers PPI as a means to achieve policy goals such
as efﬁciency, accessibility, and quality of care [26]. In the
empowerment, emancipating, or democratic rationale, PPI is anTable 1 – Description of participants in the Delphi surv
Characteristic
Sex (%)
Male
Female
Stakeholder category (multiple answers possible) (%)
Politicians, members of cabinets
Patient organizations
Sickness funds
Federal, regional, or community institutions
Representatives of medical professions or care institutions
Organizations from the associative world*
University/research
Other
Membership of advisory organs of the NIHDI (%)
Active member
Former members
Never been members
NIHDI, National Institute for Health and Disability Insurance.
* Under this heading are grouped organizations from civil society that
These are mainly the employer and employee representative organizaend in itself, focusing on the basic right of citizens to participate
in decision-making processes [6,16,26,27]. The individualistic,
capacity-building rationale sees PPI as a means to give the
population the opportunity to take up responsibility for its own
choices [28–40].
The only possible reason for PPI that did not reach consensus
was to render the health care system more demand driven
instead of supply driven. In a demand-driven system, decisions
about supply are driven by health care needs, whereas in a
supply-driven system, decisions are reactive, that is, following a
provider’s decision to supply a new product or service.ey.
Round 2 Round 3
N ¼ 107 N ¼ 80
57.0 55.0
43.0 45.0
N ¼ 107 N ¼ 80
13.1 10.0
26.1 21.3
27.1 22.5
15.9 20.0
27.1 27.5
10.3 7.5
15.0 15.0
8.4 11.3
N ¼ 105 N ¼ 80
57.1 53.7
5.7 3.7
37.1 42.5
are membership based and not directly linked to the health sector.
tions.
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According to the respondents, involving citizens and patients in
the decision-making process has two important advantages. A ﬁrst
advantage is a more in-depth understanding by the experts of
issues relating to quality of life and difﬁculties met by patients. It
brings expertise by experience from patients in the decision-
making process. A second presumed advantage is an increased
public awareness of the challenges, costs, and opportunity costs of
health care, potentially leading to an increasing individual and
collective responsibility. There was no consensus on the following
potential advantages of PPI: the possibility to develop a counter-
weight for the traditional lobbies and decision makers and the
possibility to get approval of potentially unpopular decisions.
The Delphi panel identiﬁed the following risks and problems
of PPI: insufﬁcient human and ﬁnancial means of citizens and
patients to participate effectively, the difﬁculty in ﬁnding an
adequate representation to express a collective opinion, the risk
for patients to be misused to speed up, slow down, or manipulate
the process, and the lobbying or power games of other stake-
holders. There is also a perceived risk of subjectivity. For several
risks, no consensus was reached, although the proportion of
respondents who considered them as (very) important was still
near to or up to 50%. These were the manipulation of the patient
by the industry, the diversity and multiplication of existing
representations for different diseases, the risk that more weight
will be given to the personal beneﬁts than to the common good,
the domination of protest voices, the diversity and multiplication
of existing representations on a geographical level (national,
regional, local…), and the risk of slowing down the decision-
making process.
Despite the risks identiﬁed, there was consensus among the
participants that the beneﬁts of PPI would outweigh the risks;
18% considered they would be equal and 15% considered the risks
would be superior to the beneﬁts.
Type of Decision and Role of Citizens or Patients Involved
The Delphi panel judged that for strategic decisions the involve-
ment of a citizen’s representative is the most appropriate. For
operational decisions, patient involvement was considered more
appropriate.
Patient involvement was considered especially relevant for
coverage decisions relating to high-cost pharmaceuticals, high-
volume pharmaceuticals, new diagnostic technologies, invasive
medical devices, and products and services that are today at the
charge of the patient. No consensus was reached on the rele-
vance of PPI for decisions for high-cost pharmaceuticals with low
added therapeutic value.
Intensity of Involvement
The preferred minimum level of involvement intensity and the
role of the representative depended on the type of decision.
Consensus was reached on the following: For setting global budgetary priorities in health care, the
citizen representative should at least be informed and
consulted. For decisions about the coverage of particular products, the
patient representative should at least be informed and
consulted. For decisions related to the coverage of health care products
for individual patients, there was no consensus on whether
citizens or patients should be involved at all.
Although there was consensus that consultation should
be the minimum level of involvement for both setting globalpriorities and speciﬁc coverage decisions, there was no consen-
sus on what should be the maximum level of involvement. About
24% of the participants explicitly opposed the option of partic-
ipation of citizens in the debate about health care priorities, and
25% opposed the option of participation in the debate for
decisions about the coverage of products and services. The
remainder, that is, 76% and 75%, respectively, considered partic-
ipation in the debate to be an acceptable, though not the
preferred, level of involvement. Decision making by citizens
and patients alone was explicitly rejected as an option for all
types of decision making. No single participant chose this option
as being acceptable.
Modalities of Involvement
For the two levels of involvement identiﬁed in round 1 as being
minimally required for each type of decision, the acceptability of
several practical dimensions was assessed in round 2 (Fig. 2): who
should be involved, by how many representatives, what should
be the intensity of the involvement, what should be the impact
on decision makers, where should involvement take place, and
when should it take place. In combination with the other
dimensions of involvement, they make up the involvement
models.
For both types of decisions, the preferred involvement model
was to consult the public and patients within the existing
decision-making organs and at speciﬁc milestones in the
decision-making process. More than one representative of the
public and patients was preferred to only one representative, and
changing representatives was preferred over a ﬁxed representa-
tion of citizens and patients. There was consensus among the
participants that decisions ought to be justiﬁed whenever they
differed from the advice provided by the public and patients
representatives.
Success Factors of PPI
The Delphi panel reached a consensus on the following success
factors for PPI: 1) training of public and patients and other
stakeholders to be able to contribute effectively to the decisions;
2) procedural transparency of the decision-making process; 3)
formal recognition and funding of individual patient organiza-
tions; and 4) development of a participation culture and a code of
conduct for the individuals as well as the participating associa-
tions. The respondents also agreed that a legal basis for PPI
should be developed. Finally, there was an overall perceived need
for a careful selection of the persons who would participate.
Procedural transparency refers to making explicit the role of the
citizens and patients in the decision-making process and making
transparent how their input is taken into account.Discussion
To our knowledge, this is the ﬁrst study to investigate the
acceptability of PPI in health care resource allocation decisions
for stakeholders. Even though there was consensus that PPI in
health care resource allocation decisions is important, our Delphi
panel did not unanimously agree on the importance of PPI, nor
the appropriate level of involvement. This explains at least partly
why PPI is not systematically embedded yet in decision-making
processes across the globe, despite the actual popularity of the
subject.
Another reason is the lack of evidence with respect to the
effectiveness of different PPI models in different health care
systems with different types of decision-making procedures. On
the one hand, there is a need to formulate principles of involve-
ment that can be generalized and applied across various national
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hand, participation methods need to be sensitive to and adapt-
able to local circumstances [27]. Therefore, the effectiveness of
any PPI initiative should be assessed [23] in terms of both its
implementation hurdles and achieving its predeﬁned objectives
[16].
Power inequities between actors have been highlighted as a
potential threat to the success of PPI in decision-making proc-
esses by our Delphi panel. Different actors (e.g., health care
professionals vs. patients) have different (power) positions within
the health care system, different interests and resources (e.g.,
knowledge and social capital), and different frames of reference
(expert or lay) [41]. The panel concluded that for PPI initiatives to
succeed, citizens, patients, and other stakeholders should be
trained to contribute effectively to the decisions. It is noted that
stakeholders currently involved in decision-making processes—
the majority of our Delphi panel—generally seem to expect that
citizens and patients acquire the skills to communicate with
them, rather than experts and professionals acquire the skills to
engage with the public at the public’s level. Because not all
citizens and patients will be capable of acquiring the necessary
skills, there is a risk of underrepresentation of speciﬁc population
groups and limited diversity of citizen and patient engagement.
The expectations imposed on the public and patient repre-
sentatives regarding their skills might bring along the risk of
professionalization, creating a distance between participants and
those they claim to represent. This is in the literature referred to
as the grassroots dilemma [2]. However, lack of education of
citizens and patients might increase the risk of manipulation
by other stakeholders, which was also identiﬁed by the panel as a
risk of PPI.
The panel agreed that providing sufﬁcient ﬁnancial means to
individual patient organizations could help to reduce the depend-
ency of patient organizations on private, usually pharmaceutical
company, funding. The budgetary implications of this have not
been explored, but can be expected to be large if only the
umbrella organizations are envisaged.
Our Delphi panel agreed on the fact that there is a need for
procedural transparency, recognition, and funding of patient
organizations, the development of a participation culture, and
support of all stakeholders. This corresponds with the conclusion
of Van Bovenkamp et al. [42] that the development of an
opportunity structure for PPI is a necessary but not a sufﬁcient
condition to make PPI work in practice.
A number of remarks, however, could be made with respect to
these ﬁndings in the context of the preferred PPI model of the
Delphi panel. The agreement that transparency is needed con-
curs with the preference of the panel for a model in which
deviations from the advice of the patients and citizens need to be
justiﬁed. For coverage decisions, this should happen, according to
the panel, in a context in which patients are consulted as experts.
In the current Belgian decision-making processes, this could
mean that patients are consulted regarding the expected cover-
age decision based on the advisory committee’s appraisal, or
regarding very speciﬁc decision criteria (e.g., treatment discom-
fort when the evidence regarding this criterion is limited). For the
ﬁrst, it is hard to see how patients would be able to give their
advice on the coverage if they are not allowed to really participate
in the appraisal process. For the latter, it is unclear how trans-
parent the decision maker needs to be about the other decision
criteria, for which patients are not experts. The required level of
transparency is different in cases in which patients are consulted
to give their expert advice only on a particular criterion than in
cases in which they are consulted for the ﬁnal coverage decision.
Different stakeholders might have a different idea about this.
Unfortunately, our Delphi approach did not allow examining this.
If the level of transparency can vary, the extent of justiﬁcationcan also vary: from a detailed explanation of the criteria taken
into account, with their value and relative importance, up to a
general statement explaining why a decision was taken or the
input of patients was overruled by other considerations.
Another crucial success factor for PPI is creating a participa-
tion culture. This could be achieved by means of awareness-
raising actions, an action plan with clear objectives and monitor-
ing activities, and by pilot testing PPI initiatives. A legal basis for
PPI should deﬁne the procedures for selecting representatives of
citizens and patients, the commitments of all stakeholders, and
the rules of the involvement (e.g., related to the conﬁdentiality of
commercial information). It is important to engage those stake-
holders who are currently not yet involved in decision-making
processes in the development of the action plan and the legal
basis, to get loose from the current power inequities. Only this
could ensure that the selection of representatives does not
happen in a way that de facto perpetuates the existing situation.
We recognize that our study can be criticized for a number of
reasons. First, we used the intensity ladder of involvement
proposed by the IAP2. A number of authors have criticized this
hierarchical approach, arguing that there is a considerable gap
between the degrees of participation deﬁned by the IAP2. Litva
et al. [43] show that the preferred intensity of involvement of the
public probably lies between consultation and involvement,
where involvement is deﬁned as a kind of partnership with
responsibility for decision making shared between professionals
and the public. In our Delphi survey, we also did not take into
account the option of “accountable consultation,” that is, con-
tributing to decisions by expressing views with the guarantee
that this contribution will be heard, without responsibility for the
decision, but with a view on the rationale for the decision made.
Previous research has shown that in some situations some
citizens or patients do not desire to be involved, nor share in
the responsibility [43]. This seems to apply in particular to
decisions at the individual patient level. Members of the public
do have a strong desire, however, to be involved at the system
level [43]. We included a judgment on the preferable impact of
the participation in the ﬁrst Delphi round. Both in case of global
priority setting and in case of decisions linked to speciﬁc treat-
ments, most of the respondents preferred the option of having to
justify a decision if deviant from the public’s or patients’ advice.
Second, it might be debated whether we used appropriate
cutoff points for deﬁning consensus. These cutoff points are
arbitrary. There is no scientiﬁc basis for deﬁning a threshold
value for consensus. To avoid the risk of arbitrariness in the
interpretation of results, however, we deﬁned the consensus
level a priori in the research protocol.
Third, we performed a two-round Delphi survey preceded by a
preliminary phase. More rounds clearly allow exploring elements
of consensus and disagreement more in depth. This would have
been particularly useful for exploring further the issues of trans-
parency and justiﬁcation toward patients and the public. The risk
of more rounds is, however, that people lose interest and
renounce participation.Conclusions
Belgian stakeholders seem in general to be open toward PPI in
resource allocation decision-making processes, although there are
still issues that make them reluctant to allow a more intense
involvement than consultation. The panel considers PPI impor-
tant, but at varying levels of intensity and in varying roles
depending on the type of decision. They prefer patient consulta-
tion as (external) experts for coverage decision of speciﬁc products
or services and citizen consultation for general priority decisions
in the system, in both cases within the current structures.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 7 7 – 4 8 3 483The success of PPI was considered to depend on adequate
training of all stakeholders, procedural transparency, a legal basis
for PPI, and sufﬁcient resources for and formal recognition of
patient associations. Risk factors essentially relate to the absence
of success factors, the imbalance of powers, and not ﬁnding the
adequate representation to express a collective opinion.
The present study could be a ﬁrst step in a longer process of
PPI. The next steps would be to test the actual implementation of
PPI and to evaluate its process and outcomes. PPI is a social
process, not a discrete intervention. It requires an ongoing
commitment from all stakeholders.Acknowledgments
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